

**GLOBAL HEALTH LIMITED**

ABN 75 091 377 892

**NOTICE OF ANNUAL GENERAL MEETING**

Notice is hereby given that a general meeting of the members of Global Health Limited (**Company**) will be held as shown below:

Date: **Tuesday, 21 November 2023**

Time: **3:00pm (AEDT)**

Place: **Chartered Accountants Australia and New Zealand  
Level 18 Bourke Place, 600 Bourke Street, Melbourne, Victoria 3000**

---

**ITEMS OF BUSINESS**

**Receive the Reports for the Year Ended 30 June 2023**

To receive and consider the Annual Financial Report, the Directors' Report and the Independent Audit Report of the Company and its controlled entities for the financial year ended 30 June 2023.

**Resolution 1: Remuneration Report 2023**

To consider and, if thought fit, to pass the following resolution as a non-binding resolution:

*'That the Remuneration Report for the financial year ended 30 June 2023 (as set out in the Directors' Report) be adopted.'*

Voting exclusion

The Company will disregard any votes cast on this resolution by all directors and key management personnel, being persons who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, and any of their respective nominees or associates. The Company will also disregard the votes cast on this resolution by all closely related parties of directors and key management personnel. However, the Company need not disregard a vote if it is cast by:

- (a) that person (excluded from voting) as proxy, appointed in writing for a person who is entitled to vote, in accordance with the express directions on the proxy form and is not cast on behalf of a person excluded from voting or their closely related parties; or
- (b) the person chairing the meeting who is appointed as proxy and the proxy:
  - (i) does not specify the way the proxy is to vote on the resolution; and
  - (ii) expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a member of the key management personnel for the Company.

Please note that the Chairman of the Meeting intends to vote undirected proxies in favour of all resolutions.

If the Chairman of the Meeting is appointed as your proxy, you are expressly authorising the Chairman of the Meeting to exercise your proxy even if the resolution is connected directly or indirectly with the remuneration of a member of key management personnel.

**GLOBAL HEALTH LIMITED**  
ABN 75 091 377 892

**NOTICE OF ANNUAL GENERAL MEETING 2023**

**Resolution 2: Re-election of Director**

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*‘That in accordance with ASX Listing Rule 14.4 and the Company’s Constitution, Mr Grant Smith retires by rotation and being eligible is re-elected as a Director of the Company.’*

The Directors recommend that you vote in favour of this resolution.

**Resolution 3: Approval of Issue of Equity Securities under Employee Incentive Plan**

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*“That, for the purposes of Listing Rule 7.2 Exception 13(b), and for all other purposes, approval is given for the issue of equity securities under the “Global Health Limited Equity Incentive Plan”, on the terms and conditions set out in the Explanatory Memorandum.”*

Voting exclusion

The Company will disregard any votes cast in favour of this resolution by or on behalf of any person who is eligible to participate in the Plan or any of their Associates.

However, the Company need not disregard a vote if the vote is cast by:

- (a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form;
- (b) the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary where the beneficiary has provided written confirmation that the beneficiary is not excluded from voting and is not an associate of a person excluded from voting on the resolution, and the holder votes in accordance with the directions given by the beneficiary.

The Directors abstain, in the interests of corporate governance, from making a recommendation in relation to this resolution.

**Resolution 4: Special Resolution for Approval of Additional 10% Placement Capacity under Listing Rule 7.1A**

To consider and, if thought fit, to pass the following resolution as a special resolution:

*‘That for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval be given for the issue of equity securities of up to 10% of the Company’s share capital calculated in accordance with Listing Rule 7.1A, and on the terms and conditions set out in the Explanatory Statement’.*

The Company previously obtained shareholder approval under Listing Rule 7.1A at the last Annual General Meeting on 23 November 2022.

Voting exclusion

The Company will disregard any votes cast in favour of this resolution by or on behalf of any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary shares in the Company), and any associate of any such person.

**GLOBAL HEALTH LIMITED**  
ABN 75 091 377 892

**NOTICE OF ANNUAL GENERAL MEETING 2023**

However, the Company need not disregard a vote if the vote is cast by:

- (a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form;
- (b) the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary where the beneficiary has provided written confirmation that the beneficiary is not excluded from voting and is not an associate of a person excluded from voting on the resolution, and the holder votes in accordance with the directions given by the beneficiary.

Express Authorisation of the Chair

If a Shareholder appoints the Chair as their proxy, or the Chair is appointed as the Shareholder's proxy by default, and the Shareholder does not mark a voting box for Resolution 3, then by submitting the appointment the Shareholder expressly authorises the Chair to exercise the proxy in respect of the relevant Resolution as they decide, even though the Resolution is connected with the remuneration of one or more of the Company's Key Management Personnel.

The Chair intends to vote all available proxies in favour of all Resolutions.

The Directors recommend that you vote in favour of this resolution.

The Explanatory Statement and Notes which accompany and form part of this Notice of Meeting more fully describe the matters to be considered at the Annual General Meeting.

This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers before voting.

If you wish to discuss the matters in this Notice of Meeting, please contact the Company Secretary on +613 9675 0600.

By Order of the Board



James Barrie  
Company Secretary  
20 October 2023

## NOTES

### Proxies

A member who is entitled to attend and vote at the Annual General Meeting may appoint a proxy.

A proxy need not be a member of the Company.

A proxy can be either an individual or a body corporate. If you appoint a body corporate as your proxy, that body corporate will need to ensure that it:

- appoints an individual as its corporate representative to exercise its powers at meetings, in accordance with section 250D of the Corporations Act 2001 (Cth); and
- provides satisfactory evidence of the appointment of its corporate representative prior to commencement of the meeting.

If satisfactory evidence of appointment as corporate representative is not received before the meeting, then the body corporate (through its representative) will not be permitted to act as your proxy. If a shareholder is entitled to cast two or more votes they may appoint two proxies and may specify the percentage or number of votes each proxy is appointed to exercise. If the proxy appointments do not specify the proportion or number of the member's voting rights that each proxy may exercise, each proxy may exercise half of the member's votes.

A form of appointment of proxy is enclosed. To be effective, the proxy form (and, if the appointment is signed by the appointer's attorney, the authority under which it was signed or a certified copy of the authority) must be received by the Company's share registry, Link Market Services Limited, by **3:00pm (AEDT) on Sunday, 19 November 2023**.

Where more than one proxy is to be appointed or where voting intentions cannot be adequately expressed using the enclosed proxy form, an additional form of proxy is available on request from the Share Registry.

The completed Proxy Form may be:

Mailed/delivered to the Company's share registry, Link Market Services Limited at:

**Street Address:**

Level 12  
680 George Street  
Sydney NSW 2000

**Postal Address:**

Locked Bag A14  
Sydney South  
NSW 1235

Faxed to Link Market Services Limited on fax: +612 9287 0309.

Lodged On-Line: Lodge your vote on-line at Global Health Limited's Share Registry website [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au). If you lodge your proxy electronically you will not need to return your proxy form by mail or fax.

### Corporate Representatives

A corporation may elect to appoint an individual to act as its representative in accordance with section 250D of the Corporations Act in which case the Company will require a Certificate of Appointment of Corporate Representative executed in accordance with the Corporations Act. The Certificate must be lodged with the Company before the meeting or at the registration desk on the day of the meeting. The Company will retain the certificate.

### Entitlement to Vote

*In accordance with Regulation 7.11.37 of the Corporations Regulations the Directors have set a date to determine the identity of those entitled to attend and vote at the meeting. That date is 7:00pm (AEDT) on 19 November 2023.*

## **EXPLANATORY STATEMENT**

This Explanatory Statement has been prepared for the information of Shareholders in relation to the business to be conducted at the Company's Annual General Meeting. The purpose of this Explanatory Statement is to provide Shareholders with information that is reasonably required by Shareholders to decide how to vote upon the resolutions.

The Directors recommend that Shareholders read this Explanatory Statement before determining whether or not to support the resolutions.

### **Reports for the Year Ended 30 June 2023**

This item is self-explanatory. It is intended to provide an opportunity for Shareholders to raise questions on the reports themselves and on the performance of the Company generally.

### **Resolution 1: Remuneration Report 2023**

The Remuneration Report is set out in the Directors' Report contained in the Company's 2023 Annual Report.

Section 250R(3) of the Corporations Act provides that the vote on the resolution is advisory and not binding on the Company or the Directors.

Section 250R(4) of the Corporations Act provides that votes on the resolution must not be cast (in any capacity) by or on behalf of members of key management personnel or their closely related parties. However, a vote may be cast by such a person as a proxy for a person who is entitled to vote on this Resolution, appointed by way of a shareholder voting form that directs how the proxy is to vote on this Resolution. Any undirected proxies held by Directors or by other Key Management Personnel or their closely-related parties for the purposes of this Resolution will not be voted. This prohibition does not apply to the Chairman of the meeting who may vote directed and undirected proxies in favour of the resolution, providing that the shareholder expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel for the relevant entity.

'Key Management Personnel' and 'closely related party' for the purposes of the Corporations Act are widely defined. They include directors and key management personnel of a public company and family members of directors and key management personnel. Closely-related parties include entities over which a director or key management personnel maintains control.

Under the Corporations Act, where a company's remuneration report receives a 'No' vote of 25% or more at two consecutive annual general meetings, a resolution must then be put to the shareholders at that second annual general meeting as to whether another meeting ('spill meeting') should be held within 90 days at which all directors (other than the managing director) who were in office at the date of approval of the relevant directors' report must stand for re-election.

A reasonable opportunity will be provided for discussion of the Remuneration Report at the Annual General Meeting.

The Company encourages all shareholders to cast their votes in relation to this resolution and if shareholders choose to appoint a proxy, shareholders are encouraged to direct their proxy how to vote on the Resolution by marking either "For", "Against" or "Abstain" on the proxy form.

The Chairman of the meeting intends to vote undirected proxies in favour of this resolution.

**Resolution 2: Re-election of Director**

This resolution seeks Shareholder approval for the re-election of Mr Grant Smith as a Director of the Company.

Clause 11.3 of the Company's Constitution provides that one third of the Directors shall retire from office at every Annual General Meeting and clause 11.4 provides that a retiring Director is eligible for re-election at that meeting.

If approved by Shareholders, the appointment will take effect immediately following the end of the Annual General Meeting.

Mr Smith is the Chairman of the board and a member of the Audit Committee. He has worked in insurance, superannuation, investment and funds management for over 40 years. He started with National Mutual (now AMP) in the investments division and was responsible for the establishment of the funds management business for National Mutual. In 1984, he established an independent funds management group and floated Hospitals of Australia - the first healthcare investment fund in Australia. Hospitals of Australia owned and operated a number of hospitals throughout Australia. Mr Smith was intimately involved in the building of a number of hospitals including Strathfield Private, Southern Highlands Private Hospital, Port Macquarie Hospital and the refurbishment of a number of other healthcare facilities. Hospitals of Australia was ultimately acquired by Mayne Nickless Limited. In the past 15 years, Mr Smith developed and built the Medica Centre and opened the first digital (paperless) private surgical hospital in Australia. He is currently involved in developing new hospitals in Melbourne. Mr Smith is also involved in utilising digital technology to generate increased productivity and efficiencies for the Healthcare sector.

Mr Smith has been a Director of the Company since 2013.

The Chairman of the Meeting intends to vote undirected proxies in favour of this resolution.

**Resolution 3: Approval of Issue of Equity Securities under the Global Health Limited Equity Incentive Plan**

Background

ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more equity securities during any 12-month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period.

ASX Listing Rule 7.2 (Exception 13(b)) sets out an exception to ASX Listing Rule 7.1 which provides that issues under an employee incentive scheme are exempt for a period of 3 years from the date on which shareholders approve the issue of securities under the scheme as an exception to ASX Listing Rule 7.1.

The Company has an employee incentive scheme in place called the Global Health Limited Equity Incentive Plan (**Incentive Plan** or **Plan**). Shareholders last gave approval for issues of equity securities under the Plan at the Company's 2020 Annual General Meeting. This approval expires on 30 November 2023.

The Board has resolved to amend the Incentive Plan to take account of recent changes to the Corporations Act relating to employee share schemes. The amendments to the Incentive Plan took effect on the date of this Notice of Meeting (being 20 October 2023). Accordingly, the Shareholder approval that was given for the Incentive Plan at the 2020 Annual General Meeting (which was due to expire on 30 November 2023) also expired on 20 October 2023.

Resolution 3 seeks Shareholder approval for the issue of equity securities under the Incentive Plan (as amended) for the purposes of the Corporations Act, for Listing Rule 7.2, Exception 13(b), and for all other purposes.

The aim of the Incentive Plan is to allow the Board to attract, motivate and retain eligible persons, who in the Board's opinion, are dedicated and will provide ongoing commitment and effort to the Company. It is considered that the Incentive Plan and the future issue of equity securities under the Incentive Plan will provide participants with the opportunity to participate in the anticipated future growth of the Company.

If Resolution 3 is passed, the Company will be able to issue a limited number of securities under the Incentive Plan to eligible participants over a period of 3 years without impacting on the Company's ability to issue up to 15% of its total ordinary securities without Shareholder approval in any 12 month period (as extended to 25% by the 10% Placement Facility).

If Resolution 3 is not passed, the Company will still be able to issue securities under the Incentive Plan to eligible participants, however any securities issued under the Incentive Plan will count towards its 15% capacity under ASX Listing Rule 7.1 (as extended to 25% by the 10% Placement Facility), effectively decreasing the number of securities the Company can issue without Shareholder approval over the 12 month period following the issue of any securities under the Incentive Plan.

A detailed overview of the terms of the Incentive Plan (as amended) is attached in Schedule 1. The Incentive Plan can be viewed at the "Investor Centre" tab on the Company's website ([www.global-health.com](http://www.global-health.com)).

Any future issues of securities under the Incentive Plan to a related party or a person whose relationship with the Company or the related party is, in ASX's opinion, such that approval should be obtained will require additional Shareholder approval under ASX Listing Rule 10.14 at the relevant time.

#### Specific Information Required by Listing Rule 7.2

In accordance with the requirements of Listing Rule 7.2 Exception 13(b) the following information is provided:

- (a) The material terms of the Incentive Plan are summarised in Schedule 1.
- (b) The following Equity Securities have been issued under the Incentive Plan since 30 November 2020 (the date that the Incentive Plan was approved by Shareholders) to the date of this Notice of Meeting:
  - a. 900,000 FY21 Performance Rights issued on 15 March 2021, expire 30 June 2026;
  - b. 750,000 FY22 Performance Rights issued on 1 October 2021, expire 30 June 2029, expire 12 September 2025;
  - c. 2,000,000 Options issued on 13 Sept 2022, expire 12 September 2025;
  - d. 550,030 Performance Rights issued on 13 Sept 2022, expire 31 March 2023; and
  - e. 550,030 Performance Rights issued on 13 Sept 2022, expire 31 March 2023.
- (c) The maximum number of Equity Securities proposed to be issued under the Plan is 5,804,953 Equity Securities, representing 10.0% of the number of ordinary Shares on issue as at the date of the Notice of Meeting (being 58,049,535 Shares). The maximum number of 5,804,953 Equity Securities is not intended to be a prediction of the actual number of Equity Securities to be issued under the Incentive Plan during the period for which the approval (if given) will be valid, rather it is simply a ceiling for the purposes of Listing Rule 7.2 (Exception 13(b)).

(d) A voting exclusion statement has been included for the purposes of Resolution 3.

(e) only securities that the Additional 10% can cover are existing quoted securities, namely ordinary fully paid shares.

Recommendation

Resolution 3 is an ordinary resolution.

The Directors abstain, in the interests of corporate governance, from making a recommendation in relation to Resolution 3.

The Chair intends to vote undirected proxies in favour of Resolution 3.

**Resolution 4: Approval of Capacity to Issue Additional 10% of Issued Shares under Listing Rule 7.1A**

The Company is seeking shareholder approval under this Resolution to issue up to an additional 10% of the issued share capital of the Company under ASX Listing Rule 7.1A (**Additional 10%**). This is a special resolution and requires approval of 75% of the votes cast by shareholders present and eligible to vote.

The only securities that the Additional 10% can cover are existing quoted securities, namely ordinary fully paid shares.

If Resolution 4 is passed, it will allow the Directors to issue equity securities under Listing Rule 7.1A during the period of 12 months following the Annual General Meeting without using its 15% placement capacity under Listing Rule 7.1. An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. The Company is an eligible entity.

If Resolution 4 is not passed, the Company would not be able to issue equity securities in excess of 15% of the total ordinary securities on issue in the 12 months after the Annual General Meeting without shareholder approval.

Share Issue Capacity

As at the date of this Notice of Meeting, the Company has 58,049,535 shares on issue and therefore, in addition to any other shares which it can issue under the permitted exceptions to Listing Rules 7.1 and 7.1A, it has the capacity to issue:

- 8,497,466 shares under Listing Rule 7.1; and
- subject to shareholder approval being obtained under this resolution, 5,804,953 shares under Listing Rule 7.1A.

The actual number of Shares that the Company will have the capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the shares in accordance with the following formula (as prescribed by Listing Rule 7.1A.2):

$$(A \times D) - E$$

where:

**A** is the number of fully paid ordinary securities on issue 12 months before the date of issue or agreement:

- plus the number of fully paid shares issued in the 12 months under an exception in Listing Rule 7.2;
- plus the number of partly paid shares that became fully paid in the 12 months;
- plus the number of fully paid shares issued in the 12 months with the approval of holders of shares under Listing Rule 7.1 or 7.4. This does not include an

issue of fully paid shares under the Company's 15% placement capacity without shareholder approval;

- less the number of fully paid shares cancelled in the 12 months, (note that A has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity);

D is 10%; and

E is the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that are *not* issued with the approval of holders of ordinary securities under Listing Rule 7.1 or 7.4.

Since the 2022 AGM held 23 November 2022, the Company has issued 46,154 ordinary securities to 2 employees as a one-off award in recognition of their significant contributions to the performance of the Company over the prior 6-months.

#### Minimum Issue Price

In accordance with Listing Rule 7.1A, shares issued by the Company under an Additional 10% placement can only be issued at a price that is not less than 75% of the VWAP (volume weighted average price) of the shares calculated over the 15 trading days on which trades in its shares were recorded immediately before:

- the date on which the price at which the securities are to be issued is agreed by the Company and the recipient of the securities; or
- if the securities are not issued within 10 trading days of the date on which the price is agreed by the Company and the recipient, the date on which the securities are issued.

#### Period of Validity

Shareholder approval under Listing Rule 7.1A is valid from the date of this Annual General Meeting until the earlier to occur of:

- 12 months after the date of the Annual General Meeting;
- the time and date of the next Annual General Meeting to be held; or
- the date of approval by shareholders of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking), or such longer period if allowed by ASX.

As long as on the date of the Annual General Meeting the Company meets the criteria of market capitalisation of \$300 million or less and is not included in the S&P/ASX 300 Index, shareholder approval under Listing Rule 7.1A does not lapse if the Company's market capitalisation subsequently exceeds \$300 million or it is included in the S&P/ASX 300 Index at some time during the above periods.

#### Dilution to existing shareholdings

If this Resolution is approved by shareholders and the Company issues shares under the Additional 10%, there is a risk of shareholder's interests being diluted. There is also a risk that the Additional 10% placement might raise less funding than it would if based on current market prices. This is because the market price of the Company's shares might be significantly lower on the issue date than on the date of shareholder approval, and because shares may be issued at a discount to the market price on the issue date.

As required by Listing Rule 7.3A.2, the table below shows a number of hypothetical scenarios under an Additional 10% placement where variable 'A' in the formula in Listing Rule 7.1A.2 (representing the Company's share capital) increases by either 50% or 100%, and the share price decreases by 50% or increases by 100% from the approximate share price as at the date of this Notice of Meeting.

Dilution Table - Hypothetical Potential Dilution Scenarios

Number of Shares on Issue	Dilution			
	Issue Price (per share)	\$0.083	\$0.165	\$0.248
		(50% decrease in Issue Price)	Current	(50% increase in Issue Price)
<b>58,049,535</b>	10% voting dilution	5,804,954	5,804,954	5,804,954
<b>(Current)</b>	Funds raised	\$478,909	\$957,817	\$1,436,726
<b>87,074,303</b>	10% voting dilution	8,707,430	8,707,430	8,707,430
<b>(50% increase)</b>	Funds raised	\$718,363	\$1,436,726	\$2,155,089
<b>116,099,070</b>	10% voting dilution	11,609,907	11,609,907	11,609,907
<b>(100% increase)</b>	Funds raised	\$957,817	\$1,915,635	\$2,873,452

The dilution table has been prepared on the following bases and hypothetical assumptions:

- the Company issues the maximum number of shares available under the Additional 10%;
- any increase in Variable 'A' (being the issued share capital at the time of issue) is due to an issue of shares which is an exception in Listing Rule 7.2, for example a pro-rata rights issue. However, a 15% placement under Listing Rule 7.1 does not increase variable 'A' for the purposes of calculating the placement capacity under Listing Rule 7.1A;
- the table shows only the effect of issues of shares under the Additional 10% in Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1;
- the table does not show the dilution that may be caused to any particular shareholder by reason of placements under Listing Rule 7.1A, based on that shareholder's holding at the date of the Annual General Meeting. For instance, shareholders will have different outcomes depending on whether or not they were to participate in any pro-rata issue which had the effect of increasing Variable 'A'; and
- the current share price is assumed to be \$0.165, being the closing share price on 9 October 2023 before finalising this Notice of Meeting.

Purpose of the Additional 10%

The Company may seek to issue shares under the Additional 10% for either:

- a cash issue price. In this case, the Company may use the funds for working capital or for other corporate purposes; or
- non-cash consideration, such as for the acquisition of new assets or investments, subject to any applicable ASX requirements. In these circumstances the Company will provide a valuation of the non-cash consideration as required by Listing Rule 7.1A.3.

The Company will comply with the disclosure obligations under Listing Rules 7.1A (4) and 3.10.5A upon the issue of any Additional 10%.

Allocation Policy

The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue under the Additional 10% placement. The identity of the allottees under the Additional 10% will be determined on a case by case basis having regard to factors including the following:

- the methods of raising funds that are available to the Company, including a rights issue or other issue in which existing shareholders can participate;
- the effect of the issue of the shares on the control of the Company;
- the financial situation and solvency of the Company; and

- advice from corporate, financial and broking advisors (if applicable).

The allottees under the Additional 10% placement are not known as at the date of this Notice of Meeting and may include existing substantial shareholders and new shareholders. However, the allottees cannot include any directors, related parties or associates of a related party of the Company without a further specific shareholder approval.

Previous Approval

The Company previously obtained shareholder approval under Listing Rule 7.1A at the Annual General Meeting on 23 November 2022.

During the 12-month period preceding the date of the Meeting, being on and from 23 November 2022, the Company has not issued any Equity Securities pursuant to the Previous Approval.

Recommendation

The Directors believe that this resolution will provide the Company with flexibility to raise capital quickly if advantageous terms are available and is in the best interests of the Company. The Directors recommend that shareholders vote in favour of this resolution.

The Chairman of the meeting intends to vote undirected proxies in favour of this resolution.